Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
2015 · New England Journal of Medicine · 9,325 citations
https://doi.org/10.1056/nejmoa1507643
S
Scott Gettinger
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
634
Papers
63.4K
Citations
83
h-index
211
i10-index
Scott Gettinger is an academic researcher from Yale Cancer Center. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Research Studies. The author has an h-index of 83, co-authored 539 publications.
ORCID: 0000-0003-0886-6880Papers by this author
worksPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
2014 · Nature · 5,183 citations
https://doi.org/10.1038/nature14011
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
2011 · Science Translational Medicine · 3,511 citations
https://doi.org/10.1126/scitranslmed.3002003
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
2016 · The Lancet Oncology · 987 citations
https://doi.org/10.1016/s1470-2045(16)30053-5
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
2021 · Journal of Clinical Oncology · 625 citations
https://doi.org/10.1200/jco.20.01605
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
2019 · JAMA Oncology · 613 citations
https://doi.org/10.1001/jamaoncol.2019.2187
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat